EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay

Krupa Arun Navalkar iD, Prashant Wani, Roy F Davis, Silvia Cermelli, Maximilian Dietrich iD, Maik von der Forst iD, Sören L Becker iD, Sophia Benthien, Elisa Baumann, Carsten Zeiner iD, Philipp M Lepper, José Garnacho-Montero iD und 12 weitere

Diagnostics · 03.08.2026 · 16 (15) · 2450

DOI: 10.3390/diagnostics16152450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 03.08.2026. Verfasst von Krupa Arun Navalkar und 23 weiteren Autor:innen. Beteiligte Einrichtung: Immunexpress Inc., Seattle, WA 98109, USA. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Immunexpress, Inc., Biomedical Advanced Research and Development Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overview: SeptiCyte RAPID is an FDA-cleared gene expression test that quantifies host immune response to aid in the diagnosis of sepsis. The test yields a score (the SeptiScore) ranging from 0–15, distributed across four bands (1–4) based on increased likelihood of sepsis. Each band can be characterized by average positive and negative likelihood ratios (LR+ and LR−, respectively) for the discrimination of sepsis versus the non-infectious systemic inflammatory response syndrome (SIRS).

Methods

A retrospective analysis of prospectively collected data from a combined cohort of critically ill patients suspected of sepsis (n = 889), recruited across 19 hospitals in the USA and Europe. The analysis quantified the LR+ and LR− parameters as a function of SeptiScore, for discrimination of sepsis vs. SIRS in patients admitted to ICU. Hypotheses: (1) The likelihood ratio (LR) framework provides a clinically useful interpretive approach that complements the previously used SeptiScore banding scheme; (2) Low Band 1 SeptiScores are associated with sufficiently small LR− to support the use of SeptiCyte RAPID as a rule-out test for sepsis; (3) High Band 4 SeptiScores are associated with sufficiently large LR+ to support the use of SeptiCyte RAPID as a rule-in test for sepsis; and (4) SeptiScore-derived LR+ and LR− values can be combined with estimates of pre-test probability (derived from patient characteristics and/or other diagnostic tests) to generate individualized, patient-specific post-test probabilities of sepsis.

Results

The SeptiCyte RAPID test demonstrates strong diagnostic performance in distinguishing sepsis from SIRS. The likelihood ratios across different score bands provide clear clinical utility: the median LR+ was 3.26 (range 2.57–4.24) for Band 3, and 6.97 (range 4.35–15.57) for Band 4, providing evidence toward ruling in sepsis at high SeptiScores. Conversely, the median LR− was 0.16 (range 0.14–0.20) for Band 2 and 0.085 (range 0.014–0.16) for Band 1, providing evidence toward ruling out sepsis at low SeptiScores. A higher-resolution analysis of SeptiCyte RAPID performance confirmed these trends by evaluating LR+ and LR− at specific values within each band. The sepsis group was further stratified according to whether patients were classified as blood culture positive (BC+) or blood culture negative (BC−), and the detailed LR+ and LR− analyses were repeated. A monotonic increase in likelihood ratio with increasing SeptiScore was consistently observed, independent of whether sepsis patients were culture-positive, culture-negative, or unstratified with respect to blood culture status.

Conclusions

High SeptiScores have correspondingly high LR+ values, and low SeptiScores have correspondingly low LR− values, both of which may have clinical utility. High likelihood ratios for Band 4 SeptiScores, which precede traditional microbiology results, may provide clinicians with early confidence of a sepsis diagnosis and microbiology diagnostic stewardship. Low likelihood ratios for Band 1 SeptiScores may prompt clinicians to consider an alternate diagnosis to sepsis. These are diagnostic-performance-based observations; whether they translate into fewer missed diagnoses or more efficient use of hospital resources has not been directly assessed in this study and will require dedicated clinical outcome studies.

Schlagwörter

Stichwörter der Autor:innen

SeptiCyte RAPIDSeptiScoreblood culturediagnostic accuracygene expressionhost-response biomarkerintensive care unitlikelihood ratiosepsissystemic inflammatory response syndrome

Autor:innen und Institutionen

  • Immunexpress Inc., Seattle, WA 98109, USA.
  • Department of Anesthesiology, Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 420, 69120 Heidelberg, Germany.
  • Institute of Medical Microbiology and Hygiene, Saarland University, 66421 Homburg, Germany.
  • Department of Internal Medicine V, Pneumology and Intensive Care Medicine, Saarland University, 66421 Homburg, Germany.
  • Department of Internal Medicine, Pneumology and Intensive Care Medicine, University Hospital OWL Campus Bethel, University of Bielefeld, 33617 Bielefeld, Germany.
  • Intensive Care Unit, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.

ORCID-Profile: Krupa Arun Navalkar, Maximilian Dietrich, Maik von der Forst, Sören L Becker, Carsten Zeiner, José Garnacho-Montero, María Luisa Cantón-Bulnes, Jose Luis García-Garmendia, Ángel Estella, Marcus J Schultz, Thomas D Yager

Förderung

  • Immunexpress, Inc.
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Navalkar, K. A., Wani, P., Davis, R. F., Cermelli, S., Dietrich, M., von der Forst, M., Becker, S. L., Benthien, S., Baumann, E., Zeiner, C., Lepper, P. M., Garnacho-Montero, J., Cantón-Bulnes, M. L., Fernández-Galilea, A., García-Garmendia, J. L., Estella, Á., Miller, R. R., Schultz, M. J., Rothman, R., …, & Brandon, R. B. (2026). Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay. Diagnostics, 16(15), 2450. https://doi.org/10.3390/diagnostics16152450

Vancouver

Navalkar KA, Wani P, Davis RF, Cermelli S, Dietrich M, von der Forst M, et al. Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay. Diagnostics. 2026;16(15):2450. doi:10.3390/diagnostics16152450

BibTeX
@article{Navalkar2026,
  author = {Navalkar, Krupa Arun and Wani, Prashant and Davis, Roy F and Cermelli, Silvia and Dietrich, Maximilian and von der Forst, Maik and Becker, Sören L and Benthien, Sophia and Baumann, Elisa and Zeiner, Carsten and Lepper, Philipp M and Garnacho-Montero, José and Cantón-Bulnes, María Luisa and Fernández-Galilea, Adela and García-Garmendia, Jose Luis and Estella, Ángel and Miller, Russell R and Schultz, Marcus J and Rothman, Richard and Burke, John and Patel, Gourang and Parada, Jorge and Yager, Thomas D and Brandon, Richard B},
  title = {Ruling In and Ruling Out Sepsis Using Likelihood Ratios of a Host Response Assay},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {15},
  pages = {2450},
  doi = {10.3390/diagnostics16152450}
}
Kostenlos starten →